Work

ATR Inhibition in Advanced Urothelial Carcinoma

Year: 2022

Type: article

Abstract: The ataxia telangiectasia and Rad3-related (ATR) checkpoint kinase 1 (CHK1) pathway is intricately involved in protecting the integrity of the human genome by suppressing replication stress and repairing DNA damage. ATR is a promising therapeutic target in cancer cells because its inhibition could lead to an accumulation of damaged DNA preventing further replication and division. ATR inhibition is being studied in multiple types of cancer, including advanced urothelial carcinoma where there remains an unmet need for novel therapies to improve outcomes. Herein, we review preclinical and clinical data evaluating 4 ATR inhibitors as monotherapy or in combination with chemotherapy. The scope of this review is focused on contemporary studies evaluating the application of this novel therapy in advanced urothelial carcinoma.

Source: Clinical Genitourinary Cancer

DOI: 10.1016/j.clgc.2022.10.016

Authors: Ryan C. Leibrandt, Mei-Juan Tu, Ai-Ming Yu, Primo N. Lara, Mamta Parikh

Institutions: University of California Davis Medical Center, University of California, Davis, UC Davis Comprehensive Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,070